<< Back
Biologic therapy monitoring: IDKmonitor® Adalimumab total ADA ELISA
Article number:
K 9651
96 Tests
Incubation time:
20 min; 1 h; 1.5 h; 10-20 min
25 µl
Serum, EDTA plasma
Details (PDF)
To access these files, you need the Acrobat Reader
The success of a TNFalpha blocker therapy e. g. in patients with inflammatory bowel diseases is dependent on the choice of the appropriate drug, an effective dosage and, when indicated, the administration of immunosuppressive medication. For an optimal individual control of these parameters, Immundiagnostik now offers the following contract analyses of antibodies against TNFalpha blocker:

IDKmonitor® -determination of antibodies against TNFalpha blockers
  • Specific ELISA analysis of free human antibodies against TNFalpha blocker: anti-drug-antibodies against Infliximab (e.g. Remicade®), anti-drug-antibodies against Adalimumab (e.g. Humira®) or anti-drug-antibodies against Etanercept (e.g. Enbrel®)
  • Determination of total human antibodies against Infliximab (e.g. Remicade®) or human antibodies against Adalimumab (e. g. Humira®)
  • Specific, no co-determination of rheuma factors or irregular antibodies
  • Monitoring of immunogenicity facilitates decisions on drug choice and additional medication

Contact for Immundiagnostik‘s IDKmonitor® TNFalpha blocker therapy contract analysis Jana Ruppert

Purchase Order Processing

Claudia Wandesleben / Gudrun Gutschalk
Phone: +49 6251 70190-175 /-177
Fax: +49 6251 70190-363
email: export@immundiagnostik.com

Contact Form Order Form